ALEXION PHARM (NASDAQ:ALXN)
46.91
+0.94 (2.04%)
| ALEXION PHARM (NASDAQ:ALXN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $45.97 | 52 Week High | $49.57 | ||
| Open | $46.10 | 52 Week Low | $30.78 | ||
| Day High | $47.02 | P/E | 57.91 | ||
| Day Low | $46.10 | EPS | $0.81 | ||
| Volume | 446,628 | ||||
| More ALXN Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| LH | 3 | RTN | 3 |
| CMG | 3 | POT | 2 |
| HSY | 2 | BDK | 2 |
| NFX | 2 | DHR | 2 |
| APD | 2 | DO | 2 |
| TMO | 2 | CBE | 2 |
Entities who have mentioned ALXN
- Citi | View Related Stories »
- UBS | View Related Stories »
- 13G | View Related Stories »
- Morgan Stanley | View Related Stories »
- Jefferies & Co | View Related Stories »
- David Moenning | View Related Stories »
- Deutsche Bank | View Related Stories »
- Scopia Capital | View Related Stories »
- JPMorgan | View Related Stories »
- Crude Oil | View Related Stories »
- Goldman Sachs | View Related Stories »
- Needham & Company | View Related Stories »
- Credit Suisse | View Related Stories »
- Janus Capital | View Related Stories »
- Goldman Sachs Conviction Buy List | View Related Stories »
- Soleil Securities | View Related Stories »
- Ben S. Bernanke | View Related Stories »
- Robert W Baird | View Related Stories »
- Wachovia | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- Piper Jaffray | View Related Stories »
- Collins Stewart | View Related Stories »
- Merrill Lynch | View Related Stories »
- Goldman Sachs Conviction Sell List | View Related Stories »
- Banc of America | View Related Stories »
View All Major News StreetInsider.com Major News for ALXN
- Alexion Pharmaceuticals Inc (ALXN) Posts Q3 EPS of $0.29, Beats By 8c; Guides
- Alexion Pharma (ALXN) Reports Mixed Q1 Earnings; Reaffirms Guidance
- Alexion (ALXN) Tops Q4 Views; Guides FY09 EPS Above the Street
View All ReportsStreetInsider.com Reports on ALXN
- Oppenheimer Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Perform
- Alexion Pharma (ALXN) Reports Presence of Type II PNH Cells Correlated with Thrombocytopenia
- Alexion Pharma (ALXN) Updates on Commissioning of Rhode Island Facility as Second Supply Source for Soliris
- Alexion Pharma (ALXN) Appoints William Keller to Board
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
View All Press ReleasesCompany Press Releases on ALXN
- Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results on February 11, 2010
- Alexion to Present at the 28th Annual JP Morgan Healthcare Conference
StreetInsider Reports on ALXN by Category
View All BlogsBlogs on ALXN
- Analyst upgrades, downgrades and initiations: JCG, K, MON, TOL, TXN ...
- 21 Breakout Stocks to Watch, And How to Generate Income with Apple LEAP Options
- Pundits Are Wrong: Healthcare Reform Will Increase Profits
- Ken Griffin's Citadel Fund: Options Eye Candy
- 38 Reasons the Google IPO Isn't as Big a Deal as Some Are Making It Out to Be
View All FilingsSEC Filings on ALXN
- Form SC 13G/A ALEXION PHARMACEUTICALS Filed by: BlackRock Inc.
- Form SC 13G/A ALEXION PHARMACEUTICALS Filed by: COLUMBIA WANGER ASSET MANAGEMENT LP
- Form 4 ALEXION PHARMACEUTICALS For: Jan 28 Filed by: SQUINTO STEPHEN P
- Form 4 ALEXION PHARMACEUTICALS For: Jan 28 Filed by: Hallal David
- Form 4 ALEXION PHARMACEUTICALS For: Jan 28 Filed by: DUBIN THOMAS I H
Comments on ALXN
No comments are currently available.
